Le Lézard
Classified in: Health
Subjects: SVY, BFA, TRI

Diagnosing, Treating Sleep Apnea in Hospital Improves Survival, Says Study Published by American Journal of Medicine

SAN DIEGO, Jan. 3, 2018 /PRNewswire/ -- Undiagnosed sleep apnea is highly prevalent among hospital patients, and treating it after they're discharged can improve their chances of long-term survival, according to a ResMed-funded (NYSE: RMD, ASX: RMD) study published in the American Journal of Medicine.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/74629529-resmed-sleep-apnea-study/

The study screened more than 5,000 hospitalized patients; 18.7 percent were estimated to have sleep apnea. Those who tested positive for sleep apnea were placed on positive airway pressure (PAP) therapy post-discharge. Patients who were adherent to therapy in the first three months had an improved chance of survival over the next 20 months, compared with those not adherent on PAP.

"We have a profound opportunity to identify and help tens of thousands of hospitalized patients who don't know they have a dangerous but treatable sleep condition," said Sunil Sharma, M.D., the study's principal investigator. "These results show just how important a hospital can be in addressing these issues."

"Up to 70 million Americans have sleep apnea, and only a fraction are diagnosed," said ResMed Chief Medical Officer Carlos M. Nunez, M.D. "When a medical condition brings them to a hospital, it's a prime opportunity to see if they also have sleep apnea, which they can then address ? and potentially live longer for doing so."

Read the study in the American Journal of Medicine: http://www.amjmed.com/article/S0002-9343(17)30399-6/abstract

About the study
This was a clinical pathway evaluation where 5,062 patients admitted to the Cardiology, Internal Medicine and Family Practice services with a BMI ? 30 were screened from March 2013 to July 2016. The study was approved by an Institutional Review Board. Funding support from an unrestricted grant from ResMed.

About ResMed
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients' quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com | Facebook | Twitter | LinkedIn

For media:

For investors:

Alison Graves

Agnes Lee

+1 858-836-6789

+1 858-836-5971




ResMed Inc. logo. (PRNewsFoto/ResMed Inc.) (PRNewsFoto/RESMED INC.)


Logo - https://mma.prnewswire.com/media/588826/RESMED_INC__LOGO.jpg

These press releases may also interest you

at 19:30
Arena Pharmaceuticals, Inc. today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 17th Annual Needham Healthcare Conference on Tuesday, March 27 at 3:00 p.m. EDT.  The...

at 19:08
The Honourable Ginette Petitpas Taylor, Federal Minister of Health, will be announcing federal measures to increase access to opioid treatment. Government of Canada officials will also hold a media technical briefing (teleconference only) following...

at 17:33
? LDIC Inc. (the "Manager"), the manager of Healthcare Special Opportunities Fund (the "Fund"), a closed-end investment fund, today announces the quarterly distribution of CDN$0.0535 per Class A unit and US$0.0553 per Class U unit. The distribution...

at 17:26
Home Care Assistance Cincinnati, a leading provider of in-home care for seniors, is proud to offer the first senior care solution with an emphasis on balance and longevity. The industry's most experienced and vetted caregivers undergo extensive...

at 17:19
Leaders from three of Ontario's largest unions are meeting Monday and Tuesday (March 26 and March 27, 2018) in Toronto to work together to move stalled provincial negotiations with Ontario's hospitals. Collectively the...

at 16:53
Canadian owned scientific integrator and developer, Quorum Technologies Inc. ("Quorum"), is pleased to announce the recent acquisition of the highly respected Volocity software application from PerkinElmer Health Sciences, Inc.  Volocity software has...

News published on 3 january 2018 at 09:00 and distributed by: